Merck to Acquire U.S. Biotech Firm SpringWorks Therapeutics in $3.9 Billion Deal

German pharmaceutical giant Merck KGaA has announced a major move to strengthen its oncology portfolio by agreeing to acquire U.S.-based biotech company SpringWorks Therapeutics in an all-cash deal valued at approximately $3.9 billion.

According to the agreement, Merck will pay $47 per share for SpringWorks, a 26% premium over the company’s 20-day average stock price prior to the announcement. The acquisition is expected to enhance Merck’s position in the treatment of rare tumors, an area of growing importance in its healthcare strategy.

SpringWorks adds significant value with two FDA-approved therapies: Ogsiveo (nirogacestat) for the treatment of desmoid tumors, and Gomekli (mirdametinib) for managing plexiform neurofibromas associated with neurofibromatosis type 1.

Merck stated that the acquisition is expected to immediately contribute to its revenue streams and become accretive to its earnings per share by 2027. The deal is projected to close in the second half of 2025, subject to regulatory and shareholder approvals.

This latest move highlights Merck’s ongoing commitment to expanding its innovation-driven portfolio and strengthening its footprint in the U.S. rare tumor treatment market.